Oryzon Genomics SA (ORY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oryzon Genomics SA (ORY) has a cash flow conversion efficiency ratio of -0.031x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-2.41 Million ≈ $-2.82 Million USD) by net assets (€78.54 Million ≈ $91.82 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Oryzon Genomics SA (ORY) defensive interval to measure how many days the company can operate on defensive assets alone.
Oryzon Genomics SA - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Oryzon Genomics SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Oryzon Genomics SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oryzon Genomics SA ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Akmerkez Gayrimenkul Yatirim Ortakligi AS
IS:AKMGY
|
0.014x |
|
Orge Enerji Elektrik Taahhut AS
IS:ORGE
|
-0.032x |
|
Taaleri Oyj
HE:TAALA
|
0.010x |
|
Even Construtora e Incorporadora S.A
SA:EVEN3
|
-0.038x |
|
EIH Associated Hotels Limited
NSE:EIHAHOTELS
|
0.023x |
|
GNCO Co. Ltd
KQ:065060
|
-0.009x |
|
The Gold Bond Group Ltd
TA:GOLD
|
0.012x |
|
EBEST Investment & Securities Co. Ltd
KQ:078020
|
-0.029x |
Annual Cash Flow Conversion Efficiency for Oryzon Genomics SA (2013–2025)
The table below shows the annual cash flow conversion efficiency of Oryzon Genomics SA from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see ORY market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €117.85 Million ≈ $137.78 Million |
€-2.36 Million ≈ $-2.75 Million |
-0.020x | +69.41% |
| 2024-12-31 | €87.04 Million ≈ $101.76 Million |
€-5.69 Million ≈ $-6.65 Million |
-0.065x | -829.69% |
| 2023-12-31 | €81.77 Million ≈ $95.60 Million |
€-574.96K ≈ $-672.19K |
-0.007x | +72.38% |
| 2022-12-31 | €72.57 Million ≈ $84.84 Million |
€-1.85 Million ≈ $-2.16 Million |
-0.025x | +49.97% |
| 2021-12-31 | €71.26 Million ≈ $83.31 Million |
€-3.63 Million ≈ $-4.24 Million |
-0.051x | +19.79% |
| 2020-12-31 | €75.93 Million ≈ $88.77 Million |
€-4.82 Million ≈ $-5.63 Million |
-0.063x | -29.04% |
| 2019-12-31 | €80.02 Million ≈ $93.55 Million |
€-3.93 Million ≈ $-4.60 Million |
-0.049x | -233.08% |
| 2018-12-31 | €45.13 Million ≈ $52.76 Million |
€-666.09K ≈ $-778.73K |
-0.015x | +89.20% |
| 2017-12-31 | €34.43 Million ≈ $40.25 Million |
€-4.71 Million ≈ $-5.50 Million |
-0.137x | +37.94% |
| 2016-12-31 | €22.73 Million ≈ $26.57 Million |
€-5.01 Million ≈ $-5.85 Million |
-0.220x | -1262.00% |
| 2015-12-31 | €27.59 Million ≈ $32.26 Million |
€523.14K ≈ $611.61K |
0.019x | -97.83% |
| 2014-12-31 | €13.89 Million ≈ $16.24 Million |
€12.13 Million ≈ $14.18 Million |
0.873x | +6.01% |
| 2013-12-31 | €14.73 Million ≈ $17.22 Million |
€12.13 Million ≈ $14.18 Million |
0.823x | -- |
About Oryzon Genomics SA
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-… Read more